Skip to main content

Table 4 Overview of literature for the laparoscopic staging procedure in early-stage ovarian cancer

From: Increasing experience in laparoscopic staging of early ovarian cancer

Laparoscopy

Number

Restaging/primary staging

OR time (min)

Delay (weeks)

Hospital stay (days)

PLN (n)

PALN (n)

EBL (ml)

Upstaging (n, %)

Compl (n, %)

Follow-up (months)

R (n)

M (n)

Present series

25

24/1

224 (100–285)

7.3 (3.1–13.3)

4.0 (2–6)

13.8 (3–31)

5.8 (2–12)

193 (10–1,500)

8 (32%)

4 (16%)

43 (1–116)

5

2

Nezhat et al. [16]

36

9/25

229 (59–386)

NA

2.37 (1–5)

14.84 (0–45)

12.23 (0–53)

195 (25–500)

7 (19.4%)

4 (11.1%)

56

3

0

Muzii et al. [15]

27

27/0

180 (130–300)

6.8 (2–9)

3 (2–7)

NA

NA

200 (100–700)

7 (26%)

1 (3.7%)

20 (7–38)

1

0

Jung et al. [12]

24

5/19

253.7 ± 65.7

NA

10.6 ± 4.0

22.5 ± 8.9

11.0 ± 5.8

567.0 ± 170.9

10 (41.7%)

1 (4.2%)

10 (2–39)

1

1

Park et al. [17]

19

7/12

221 ± 83

19 (7–34)

8.9 ± 6.1

27.2 ± 9.7

6.6 ± 6.2

240 ± 228

4 (21.1%)

2 (10.5%)

17 (2–40)

0

0

Park et al. [18]

17

6 / 11

303.8 ± 84.9

35.8

9.4 ± 4.1

13.7 ± 5.6

8.9 ± 7.1

231.2 ± 117.9

1 (5.9%)

2 (11.8%)

19 (5–56)

2

1

Colomer et al. [10]

20

7/13

223 (180–320)

4.7 (2–11.4)

3.2 (1–7)

18 (14–21)

11.3 (7–23)

NA

4 (20%)

2 (10%)

24.7 (1–61)

1

0

Ghezzi et al. [11]

15

5/10

377 ± 47

8 (5–14)

3 (2–12)

25.2 ± 9.3

6.5 ± 3.9

250 (50–1,000)

4 (26.7%)

2 (6.7%)

16 (4–33)

0

0

Chi et al. [8]

20

13/7

321 ± 64

NA

3.1 ± 0.7

L, 5.8 ± 2.9

L, 2.9 ± 1.7

235 ± 138

NA

0

NA

NA

NA

R, 6.5 ± 3.9

R, 3.8 ± 1.8

Spirtos et al. [21]

58

58/0

187.9 ± 59.8

NA

3.35 ± 5.10

L, 9.0 ± 6.0

L, 5.3 ± 3.3

171.9 ± 128

8 (13.8%)

11 (19%)

NA

NA

0

R, 9.6 ± 5.2

R, 5.0 ± 3.4

Leblanc et al. [14]

53

42/11

238 (120–370)

8.3 ± 4.8

3.1 (1–5)

14 (4–27)

20 (7–40)

NA

8 (19%)

4 (7.5%)

54 (8–116)

5

2

Krivak et al. [30]

19

0/19

201 (90–350)

NA

2 (1–8)

NA

NA

271 (50–1,500)

7 (36%)

4 (16%)

32

NA

NA

Tozzi et al. [22]

24

11/13

176 (102–306)

12 (4–21)

7 (5–12)

19.8 (14–29)

19.6 (5–35)

NA

NA

1 (4.1%)

46 (2–72)

2

0

Leblanc et al. [13]

28

25/3

230 ± 67.5

8.3 (2–26)

3.3 (1–6)

13.7 (4–27)

19.7 (5–40)

NA

6 (21%)

1 (3.7%)

38 (2–89)

1

1

Amara et al. [7]

4

3/1

290 (190–335)

NA

1.75 (1–2)

NA

NA

NA

NA

0

NA

NA

NA

Pomel et al. [19]

10

10/0

313

NA

4.75 (2–8)

7.1 (3–13)

8.8 (6–12)

NA

NA

2 (20%)

NA

NA

NA

Childers et al. [9]

14

5/9

149 (120–240)

NA

1.6 (0–3)

NA

NA

NA

8 (57%)

2 (14.3%)

NA

NA

NA

Querleu and Leblanc [20]

9

9/0

227 (130–360)

NA

2.8 (1–5)

NA

8.6 (5–17)

<300

0%

0

NA

NA

NA

Laparotomy

Park et al. [17]

33

NA

275 ± 63

13 (9–16)

14.5 ± 5.6

33.9 ±14.5

8.8 ± 8.1

568 ± 451

7 (21.2%)

9 (27.3%)

23 (1–44)

0

0

Park et al. [18]

19

NA

290 ± 121

32

14.1 ± 4.2

19.3 ± 10.1

6.4 ± 3.9

505.3 ± 279.8

6 (31.6%)

7 (36.8%)

14 ( 5–61)

0

0

Ghezzi et al. [11]

19

NA

272 ± 81

NA

7 (4–14)

25.1 ± 5.8

7 ± 4.5

400 (150–1,000)

6 (31.6%)

8 (42.1%)

60 (32–108)

4

0

Chi et al. [8]

30

NA

276 ± 68

NA

5.8 ± 2.6

L, 7.1 ± 4.3

L, 4.8 ± 4.2

367 ± 208

NA

2 (7%)

NA

NA

NA

R, 7.6 ± 3.8

R, 4.4 ± 2.8

Spirtos et al. [21]

17

NA

218 ± 73

NA

7.31 ± 9.3

L, 8.2 ± 5.0

L, 4.6 ± 2.6

352.8 ± 415.0

8 (47%)

NA

NA

NA

0

R, 9.14 ± 9.9

R, 4.4 ± 2.7

  1. Delay between initial OR and staging, PLN pelvic lymph nodes, PALN para-aortic lymph nodes, EBL estimated blood loss, Compl complications, R Recurrence, M Mortality (depending on what authors describe NA not available, range, ± standard deviation)